ClinicalTrials.gg
RecruitingNCT07014826Updated Aug 5, 2025

A Trial of HRS-5965 Capsule in Primary IgA Nephropathy

A Phase 3 interventional study of HRS-5965 and Placebo in Primary IgA Nephropathy, sponsored by Chengdu Suncadia Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-05.

Sponsored by Chengdu Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
378
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Glomerulonephritis, IGA by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 3 under way, 1 of them phase 3. Glomerulonephritis, IGA · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
2nd of 11
378 · median 61
Started
2025
with 1 other
Phase 3
Only one
of the 11
Registered
8th of 11
by date

Among the 11 studies in Glomerulonephritis, IGA by Jiangsu HengRui Medicine Co., Ltd., this one is the 2nd largest by planned enrollment, is one of 2 that started in 2025, is the only one in phase 3, and was the 8th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

3 of the 11 studies in Glomerulonephritis, IGA by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Glomerulonephritis, IGA by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This multicenter, randomized, double-blind, parallel, placebo-controlled study is being conducted to evaluate the efficacy, and safety of HRS-5965 capsule for primary IgA nephropathy.

03

Conditions studied

  • Primary IgA Nephropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written ;
  2. Weight ≥35 kg, (BMI) \< 37.5kg /m2;
  3. Primary IgA nephropathy was confirmed by renal within 8 years;
  4. 24-UPE≥ 1.0g /24h, or 24-UPCR≥ 0.8g/g at screen, and 24-UPCR≥ 0.8g/g prior to randomization;
  5. ≥30 ml/min/1.73m2 at screening and prior to randomization; (CKD-EPI formula)
  6. A fertile female subject or a male subject whose partner is a fertile female, who has not had a fertility, sperm/egg donation plan from the signing of the informed consent to 1 month after the last dose, and voluntarily takes effective measures (including the partner);
  7. Understand the research procedures and methods, voluntarily participate in this trial, and sign the informed consent form in person.
  8. Receiving optimal supportive therapy including RAS blockers and stabilizing the dose for at least 12 weeks after reaching the maximum recommended dose or the maximum tolerated dose prior to randomization;

Exclusion criteria

Exclusion Criteria:

  1. Allergic to any RAS blockers, products, or components as evaluated by the investigator;
  2. Patients with secondary IgA nephropathy as determined by the investigator;
  3. IgA nephropathy with rapid decline of renal function; Kidney pathology indicated that more than 50% of the glomerulus had large crescent body formation, which may affect the study results; Tubule atrophy - interstitial fibrosis of more than 50%;
  4. Patients with a history of immunodeficiency disease; Or in combination with other systemic diseases likely to cause proteinuria; Or with Nephrotic Syndrome;
  5. Have any organ transplant;
  6. Patients with active infection of tuberculosis within 1 year prior to screening, such as liver abscess and pyelonephritis; Or subjects with active infection who requiring intravenous antibiotic therapy within 2 weeks prior to randomization;
  7. Patients with a history of malignant neoplasms;
  8. Patients with a history of severe trauma or major surgery within 12 weeks prior to screening, or who plan to undergo surgery during the study period;
  9. Patients with a history of blood donation or a history of severe blood loss (≥400 mL blood loss) within 12 weeks prior to screening, or who have received blood transfusions within 12 weeks prior to screening;
  10. The presence of a disease or medical condition determined by the investigator might affect drug absorption, distribution, metabolism, and excretion;
  11. As determined by the investigator, the subject has any of the following: progression or recovery of a disease;
  12. (ALT), Aspartate aminotransferase (AST), or total exceeding 3 times the (ULN) at screening;
  13. Participants who have participated in a clinical trial of any drug or medical device within 12 weeks prior to randomization and are expected to have residual effects of the investigational treatment (as determined by the investigator), or who were within the follow-up period of a clinical study, or within 5 half-lives of the investigational drug, or within 30 days (whichever is older) before screening;
  14. Women who are pregnant or breastfeeding;
  15. A history of drug abuse;
  16. Participants who received systemic or immune suppressants within 12 weeks prior to randomization and are expected to have during research;
  17. Participants who received biologics or cytokine inhibitor within 6 months prior to randomization and are expected to have during research;
  18. Any physical or mental illness or condition that, as determined by the investigator, is likely to increase the risk of the study, affect the subject's adherence to the protocol, or prevent the subject from completing the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
378 participants (estimated)

Study arms

  • Experimental
    Treatment group A

    HRS-5965

    Drug: HRS-5965

  • Placebo comparator
    Treatment group B

    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Ratio of 24-hour Urinary protein to creatinine ratio (UPCR) to baseline

    Time frame: Baseline and Week 36

  2. The total annualized slope of estimated glomerular filtration rate(eGFR)

    Time frame: Baseline and Week 104

Secondary outcomes

  1. The total annualized slope of estimated glomerular filtration rate(eGFR)

    Time frame: up to Week 36

  2. Proportion of subjects with 24-hour urinary protein excretion (24-UPE) < 0.5 g/d and < 0.3 g/d

    Time frame: up to Week 36 and Week104

  3. Proportion of subjects with 24-UPCR declined >50% to baseline

    Time frame: up to Week 36 and Week104

  4. Ratio of 24-hour Urinary protein to creatinine ratio (24-UPCR) to baseline

    Time frame: up to Week 36 and Week104

  5. Ratio of 24-hour Urinary protein to Albumin Creatinine ratio (24-UACR) to baseline

    Time frame: up to Week 36 and Week104

  6. Ratio of 24-hour Urinary protein excretion(24-UPE) to baseline

    Time frame: up to Week 36 and Week104

  7. Change from baseline of eGFR

    Time frame: up to Week 36 and Week104

  8. Change from baseline of serum creatinine

    Time frame: up to Week 36 and Week104

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Oct 2027, 28 months after the start.

Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's planned 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
Jun 11, 2025
StartActual
Jun 4, 2025
Primary completionEst.
Oct 2027
CompletionEst.
Dec 2028
Last update
Aug 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07014826
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Jun 4, 2025
Primary completion
Oct 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Aug 5, 2025

Study contacts

Sheng Qi
Contact
Sheng.qi@hengrui.com
+86 0518 82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-5965

Start the discussion